Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 237

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Max S. Topp, MD, Johannes Duell, MD, Jingjin Li, PhD, Vladimir Jankovic, MD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Lieve Adriaens, PharmD, Mary Peterman, PharmD, Srikanth R. Ambati, MBBS, MD, Rajat Bannerji, MD PhD

Blood (2019) 134 (Supplement_1): 4007.

https://doi.org/10.1182/blood-2019-126670

Published: 2019

Journal Articles

A Multi-Institutional Validation of the Prognostic and Predictive Value of the Neutrophil-to-Lymphocyte Ratio in Patients with Diffuse Large B- Cell Lymphoma: A Study from the Latin American Working Group for Lymphomas (GELL)

Blood (2019) 134 (Supplement_1): 4121.

https://doi.org/10.1182/blood-2019-127479

Published: 2019

Journal Articles

Treatment Outcome and a Practical 10-Point Prognostic Index in Adult Patients with Non-M3 Acute Myeloid Leukemia: A Retrospective, Multicenter Study in Malaysia

Tze Shin Leong, MBBS,MRCP,MSc, Sen Mui Tan, Lee Ping Chew, Tee Chuan Ong, Siew Lian Chong, Kar Ying Yong, Siong Leng Hon, Syazarin Fidhora Nasution, Ching Tiong Ko, Vanusha Devaraja, Andy Sing Ong Tang, Tsen Chuen Jerome Tan, Ngee Siang Lau, Sharifah Shahnaz Syed Abd Kadir, Veena Selvaratnam, Yee Yee Yap, Bee Sun Lee, William Kian Boon Law, Jameela Sathar

Blood (2019) 134 (Supplement_1): 2606.

https://doi.org/10.1182/blood-2019-126656

Published: 2019

Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD

Blood (2019) 134 (Supplement_1): 2593.

https://doi.org/10.1182/blood-2019-123045

Published: 2019

Journal Articles

Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)

Hui-qiang Huang, MD PhD, Rong Tao, MD PhD, Liqun Zou, Hong Cen, MD PhD, Ye Guo, MD PhD, Yunhong Huang, MD PhD, Wenbin Qian, MD PhD, Liling Zhang, MD PhD, Hui Zhou, MD PhD, Yu Yang, MD PhD, Haiyan Yang, Dan Zhu, Teng Fang, PhD, Hangjun Dai, Yueling Wang, Jianxin Yang, MD PhD

Blood (2019) 134 (Supplement_1): 2833.

https://doi.org/10.1182/blood-2019-121865

Published: 2019

Journal Articles

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Hiroyuki Takamatsu, MD PhD, Shohei Mizuno, MD PhD, Tsutomu Takahashi, MD PhD, Shin-Ichi Fuchida, MD PhD, Ichiro Hanamura, MD PhD, Fumihiko Nakamura, MD PhD, Takehiko Mori, MD PhD, Yuta Katayama, MD PhD, Noriko Doki, MD PhD, Nobuhiro Tsukada, MD PhD, Tatsuo Ichinohe, Yoshinobu Kanda, MD PhD, Yoshiko Atsuta, MD PhD, Kazutaka Sunami, MD PhD

Blood (2019) 134 (Supplement_1): 4358.

https://doi.org/10.1182/blood-2019-123607

Published: 2019

Journal Articles

Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey

Wenrui Yang, MD, Bing Han, MD PhD, Hong Chang, MD, Bingyi Wu, MD, Fankai Meng, Dexiang Ji, MD, Yingmei Li, MD, Zhengjin Zheng, MD, Yan Fei, Jianping Shen, MD, Ping Hu, MD, Jianxiang Wang, MD, Fengkui Zhang, MD

Blood (2019) 134 (Supplement_1): 5020.

https://doi.org/10.1182/blood-2019-126441

Published: 2019

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug Trials

Jessica K Roydhouse, PhD MPH, Vishal Bhatnagar, MD, Tara Berman, MD, Laurel A Menapace, MD, Rajiv Agarwal, Mallorie H. Fiero, PhD, Paul Kluetz, MD

Blood (2019) 134 (Supplement_1): 4769.

https://doi.org/10.1182/blood-2019-124168

Published: 2019

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

Blood (2019) 134 (Supplement_1): 412.

https://doi.org/10.1182/blood-2019-126837

Published: 2019

Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 5244.

https://doi.org/10.1182/blood-2019-124326

Published: 2019

Journal Articles

Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore

Ya Hwee Tan, MBBS, MRCP, Siqin Zhou, MSc, Liu Xin, Soon Thye Lim, MBBS, MRCP, FAMS, Miriam Tao, MBBS, FAMS, FHKAM, FHKCP, MRCP, Daryl Tan, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Mohamad Farid, MBBS, MMed, MRCP, Colin Phipps Diong, Yuh Shan Lee, Shin-Yeu Ong, MD, Nicholas Francis Grigoropoulos, Kheng Wei Yeoh, MBBS, MSc, MRCP, MPH, FRCR (Clinical Oncology), Nagavalli Somasundaram, MBBS, MRCP, Eileen Yi Ling Poon, MBBS, MRCP, MMED, Jason Yongsheng Chan, MBBS, MRCP, Esther Wei Yin Chang, MD MRCP, Tiffany Tang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 5274.

https://doi.org/10.1182/blood-2019-125085

Published: 2019

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

Naomi Aoki, MSc, BSc, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Zoe McQuilten, Cameron Wellard, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2019) 134 (Supplement_1): 5518.

https://doi.org/10.1182/blood-2019-124256

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Risk of Second Primary Malignancy in Multiple Myeloma in the Novel Therapy Era from 15 Years of Cancer Registry

Hsin-An Hou, Yanfang Liu, MD MPH, Hong Qiu, MD PhD, Hwei-Fang Tien, MD, PhD, Chao-Hsiun Tang

Blood (2019) 134 (Supplement_1): 1878.

https://doi.org/10.1182/blood-2019-124296

Published: 2019

Journal Articles

One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)

Blood (2019) 134 (Supplement_1): 2035.

https://doi.org/10.1182/blood-2019-125232

Published: 2019

Journal Articles

A Cross-Sectional Study Examining the Effects of Patient Information Level on Healthcare Experience in 2 Patient Populations: Extranodal Natural Killer T-Cell Lymphoma (ENKTL) and Waldenstrom Macroglobulinemia (WM)

Natalie M Dren, BSc, MPH, Lorna E Warwick, BA, B Ed, Olufunmilayo A Bamigbola, MB;BS, MSc (Epid)

Blood (2019) 134 (Supplement_1): 3422.

https://doi.org/10.1182/blood-2019-123479

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

A Multi-Institutional Validation of the Prognostic and Predictive Value of the Neutrophil-to-Lymphocyte Ratio in Patients with Diffuse Large B- Cell Lymphoma: A Study from the Latin American Working Group for Lymphomas (GELL)

Treatment Outcome and a Practical 10-Point Prognostic Index in Adult Patients with Non-M3 Acute Myeloid Leukemia: A Retrospective, Multicenter Study in Malaysia

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug Trials

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Risk of Second Primary Malignancy in Multiple Myeloma in the Novel Therapy Era from 15 Years of Cancer Registry

One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)

A Cross-Sectional Study Examining the Effects of Patient Information Level on Healthcare Experience in 2 Patient Populations: Extranodal Natural Killer T-Cell Lymphoma (ENKTL) and Waldenstrom Macroglobulinemia (WM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only